Phanes Therapeutics, Inc.
↗San Diego, California, USA
Phanes Therapeutics, Inc. is a San Diego-based biotechnology company focused on the discovery and development of innovative immunooncology therapeutics. Founded in July 2016 by a team of industry veterans with extensive experience from leading pharmaceutical companies (Pfizer, Amgen, Johnson & Johnson), Phanes specializes in developing bispecific antibodies targeting immuno-oncology pathways. The company has developed three proprietary technology platforms—PACbody®, ATACCbody®, and SPECpair®—designed to create native IgG-like bispecific antibodies with improved stability, manufacturability, and clinical properties. Phanes is advancing a pipeline of first-in-class bispecific antibodies in clinical development for solid tumors, with multiple programs receiving FDA Fast Track designations and orphan drug designations. The company is advancing Phase 1/2 clinical trials for three lead programs targeting multiple oncology indications including pancreatic cancer, gastric cancer, small cell lung cancer, and neuroendocrine carcinomas.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue (Clinical stage)
Founded:2016
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$40M
Investors:Sequoia Capital China, K2VC, HongShan Capital, Delos Capital Partners, DYEE Capital, Volcanics Venture
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Bispecific antibodies, Native IgG-like bispecific antibodies, Monoclonal antibodies
Active Trials:3
Trial Phases:Phase 1: 3 | Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Merck (MSD) - Clinical collaboration for PT886 (Spevatamig) in combination with KEYTRUDA®, Roche - Clinical supply agreement for PT217 (Peluntamig) in combination with atezolizumab, Xyphos Biosciences (Astellas) - Research collaboration leveraging PACbody™ and SPECpair™ platforms for cell therapies, CrownBio - Strategic partnership for in vivo pharmacology and efficacy modeling (MuPrime™, HuGEMM™, PDX models)
COMPETITION
Position:Emerging
Competitors:Cantex Pharmaceuticals, Kymera Therapeutics, Byondis, CytomX Therapeutics, Inovio Pharmaceuticals, Gliknik, Enterprise Therapeutics, Centrose +3 more
LEADERSHIP
Key Executives:
Ming Wang, PhD - Founder, President and CEO
Hui Zou, PhD - Chief Scientific Officer (CSO) and Executive VP
Rita Laeufle - Chief Medical Officer (CMO)
Chong Wang, PhD - Senior Vice President of Corporate Affairs
Paul Chu - Vice President Business Development
Chelsea Johnson, RN - Senior Director, Clinical Science and Operations
Scientific Founders:Ming Wang, PhD
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Phanes Therapeutics, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.